Prostate-specific membrane antigen PET (PSMA-PET) has emerged as a powerful imaging tool for prostate cancer primary staging, biochemical recurrence, and advanced disease assessment.
This article offers a concise overview of the benefits and challenges associated with PSMA-PET for prostate cancer evaluation.
The article highlights the advantages of PSMA-PET over conventional imaging, such as its higher sensitivity and specificity for detecting metastases, and the potential for guiding personalized treatment decisions.
However, it also explores the limitations and potential pitfalls for interpretation.
Overall, the article aims to provide valuable insights for clinicians and diagnostic imaging physicians in clinical practice.
